During vascular intervention oxidized low-density lipoprotein (oxLDL) and lysophosphatidylcholine (lysoPC) accumulate at the site of arterial injury, which inhibits endothelial cell (EC) migration, and impedes endothelium healing. We have previously shown that lysoPC activates canonical transient receptor potential 6 (TRPC6) channel that leads to a prolonged [Ca2+]i influx, causing the inhibition in EC migration. We hypothesize that lysoPC activates phospholipase A 2 (PLA 2 ) crucial for TRPC6 activation; PLA 2 acts on cellular membranes to release arachidonic acid that opens arachidonate regulated calcium channel to release the initial calcium required to trigger TRPC6, blocking PLA 2 will prevent the opening of TRPC6 channels, preserve migration and promote endothelium healing. After incubation of bovine aortic EC with ATK or Ax048 to block PLA2G4, or with BEL, FKGK11, or FKGK18 to block PLA2G6, the effect of lysoPC-induced TRPC6 externalization and EC migration was assessed. Reversible PLA2G6 pharmacological inhibitors maximally blocked lysoPC-induced TRPC6 externalization, arachidonic acid release and preserved EC migration; exemplified with biotinylation assay, arachidonate enzyme assay, and razor scrape migration assay respectively. Immunofluorescence microscopy for TRPC6 plasma membrane translocation and PLA 2 enzyme activity assay supported these findings. To further verify the specific isoforms involved in blocking TRPC6 externalization, siRNA mediated transient knockdown studies were performed with PLA2G4A, PLA2G4C, PLA2G6A, and PLA2G6B siRNAs in EA.hy926— human endothelial cell line. PLA2G6A and not PLAG6B/4A/4C downregulation completely blocked TRPC6 externalization and preserved migration comparable to control levels. These studies confirmed the role of PLA2G6A (a calcium-independent cytosolic phospholipase A 2 group VI β isoform) in blocking lysoPC-induced TRPC6 activation and preservation of EC migration. Additional studies are in progress to confirm in vivo relevance of these findings. Our results show the potential for developing PLA 2 targeted therapies to block TRPC6 activation and promote endothelium healing, thus improving the outcomes for patients undergoing cardiovascular intervention.
Read full abstract